Table 3

Incremental cost-effectiveness ratios (ICERs)

ICERICER corrected for biasNormal CIPercentile CI (95%)Normal CI
(corrected for bias)
TargetSimple−101.21 –
Non-parametric BS−104.55−97.87(−107.88 to −101.21)(−352.59 to 120.26)(−101.21 to −94.53)
Univariate parametric BS−96.58−105.84(−99.77 to −93.38)(−312.78 to 144.74)(−109.03 to −102.65)
Multivariate parametric BS−96.91−105.51(−99.84 to −93.99)(−301.26 to 116.96)(−108.43 to −102.59)
HyperSimple−369.22 –
Non-parametric BS−395.93−342.51(−408.95 to −382.91)(−1380.61 to 467.07)(−355.53 to −329.49)
Univariate parametric BS−379.03−359.41(−391.94 to −366.12)(−1,294.23 to 537.07)(−372.32 to −346.50)
Multivariate parametric BS−411.09−327.35(−424.28 to −397.91)(−1,442.43 to 437.01)(−340.54 to −314.16)
HypoxSimple−1565.46 –
Non-parametric BS−1709.95−1420.97(−1766.64 to −1653.25)(−6265.24 to 1894.99)(−1477.67 to −1364.27)
Univariate parametric BS−1661.46−1469.46(−1718.62 to −1604.29)(−5,911.79 to 2367.25)(−1526.62 to −1412.30)
Multivariate parametric BS−2250.04−880.88(−4841.99 to 341.92)(−17 091.61  to 6560.38)(−3472.84 to 1711.01)
  • Target, percentage of time spent at the target SpO2.

  • BS, bootstrap; Hyper, percentage of time spent in hyperoxia (SpO2+5% above the target); Hypox, percentage of time spent in hypoxaemia (SpO2 <85%).